Clinical validation of the Tempus xO assay

We have developed a clinically validated NGS assay that includes tumor, germline and RNA sequencing. We apply this assay to clinical specimens and cell lines, and we demonstrate a clinical sensitivity of 98.4% and positive predictive value of 100% for the clinically actionable variants measured by t...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaubier, Nike, Tell, Robert, Huether, Robert, Bontrager, Martin, Bush, Stephen, Parsons, Jerod, Shah, Kaanan, Baker, Tim, Selkov, Gene, Taxter, Tim, Thomas, Amber, Bettis, Sam, Khan, Aly, Lau, Denise, Lee, Christina, Barber, Matthew, Cieslik, Marcin, Frankenberger, Casey, Franzen, Amy, Weiner, Ali, Palmer, Gary, Lonigro, Robert, Robinson, Dan, Wu, Yi-Mi, Cao, Xuhong, Lefkofsky, Eric, Chinnaiyan, Arul, White, Kevin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995233/
https://www.ncbi.nlm.nih.gov/pubmed/29899824
http://dx.doi.org/10.18632/oncotarget.25381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995233/
https://www.ncbi.nlm.nih.gov/pubmed/29899824
http://dx.doi.org/10.18632/oncotarget.25381

Ejemplares similares